Abstract: The inhibitory oligonucleotides (ODNs) which strongly block NF-?B activation induced by TLR9 agonists and TLR7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-ODNs. Interferon production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-ODNs. These ODNs can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes.

Abstract: A polyurethane foam having an initial UL 94 vertical flame classification of V-0 and maintaining a UL 94 vertical flame classification of V-0 after one week of heat aging at 150° C. is formed as the reaction product of an isocyanate component and an isocyanate-reactive component in the presence of a blowing agent. The isocyanate component includes an isocyanate-containing compound and a non-reactive phosphorous compound that is present in an amount ranging from 1 to 20 weight percent based on the total weight of the polyurethane foam. The isocyanate-reactive component includes a polyether polyol and expandable graphite that is present in an amount ranging from 3 to 30 weight percent based on the total weight of the polyurethane foam.

Abstract: The inhibitory oligonucleotides (ODNs) which strongly block NF-?B activation induced by TLR9 agonists and TLR7 agonists are provided. The production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor alpha, is inhibited by the inhibitory-ODNs. Interferon production from human PBMC induced by TLR9 agonist is prevented by the inhibitory-ODNs. These ODNs can be used as a remedy for the treatment of immune-mediated disorders such as rheumatoid arthritis, systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes.

Abstract: An oligonucleotide with a nucleotide sequence of 5?-cctcctcctcctcctcctcctcct-3? (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can be used as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and other immune-mediated disorders.

Abstract: The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or other vaccines, the adjuvant can significantly improve the immune effect of the vaccine.

Abstract: An oligonucleotide with a nucleotide sequence of 5?-cctcctcctcctcctcctcctcct-3? (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can be used as a remedy for the treatment of systemic lupus erythematosus (SLE), sepsis, multiple organ dysfunction syndromes and other immune-mediated disorders.

Abstract: The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or other vaccines, the adjuvant can significantly improve the immune effect of the vaccine.

Abstract: The present invention provides a series of artificial CpG-containing single-stranded oligodeoxynucleotides (ODNs), each of which is consisted of single-stranded oligodeoxynucleotide DNA molecule containing one or more CpG(s), wherein said ODNs can stimulate human peripheral blood mononuclear cell (PBMC) to produce antiviral substances. These ODNs can protect the cells against the attack from virus, wherein said virus is preferably selected from the group consisted of influenza virus and single-stranded positive strand RNA virus such as SARS virus, hepatitis C virus, dengue virus and Japanese encephalitis virus. Moreover, the antiviral use of artificial CpG ODNs and its use for treating and preventing viral infection are also provided.

Abstract: The present invention provides an adjuvant, which includes at least one single strand deoxynucleotide containing a CpG dinucleotide. The single strand deoxynucleotide comprises one or more CpG dinucleotides. When used in combination with rabies vaccine, HBV vaccine or other vaccines, the adjuvant can significantly improve the immune effect of the vaccine.

Abstract: The present invention provides a series of artificial CpG-containing single-stranded oligodeoxynucleotides (ODNs), each of which is consisted of single-stranded oligodeoxynucleotide DNA molecule containing one or more CpG(s), wherein said ODNs can stimulate human peripheral blood mononuclear cell (PBMC) to produce antiviral substances. These ODNs can protect the cells against the attack from virus, wherein said virus is preferably selected from the group consisted of influenza virus and single-stranded positive strand RNA virus such as SARS virus, hepatitis C virus, dengue virus and Japanese encephalitis virus. Moreover, the antiviral use of artificial CpG ODNs and its use for treating and preventing viral infection are also provided.

Abstract: Certain embodiments of the invention provide a fusion protein comprising Bacillus Calmette Guérin heat shock protein 65 and one to five copies of the epitope of human prostate specific antigen. The fusion protein provided by certain embodiments is therapeutic and/or preventive to human prostate cancer. Certain embodiments also provide the nucleic acid molecule encoding the fusion protein.

Abstract: Certain embodiments described herein provide a fusion protein comprising Bacillus Calmette Guérin (BCG) heat shock protein 65 (HSP65) and 1 to 5 copies of the epitope of MUC1, which is therapeutic and/or preventive to human MUC-1 expressing carcinomas including breast cancer, ovarian cancer, colon cancer, prostate cancer and lung cancer. Certain embodiments described herein provide a nucleic acid encoding the fusion protein, a recombinant plasmid containing the nucleic acid, a host cell transformed with the recombinant plasmid and/or a method for preparing the fusion protein by culturing the host cells.